Literature DB >> 32285272

The Chicago Consensus on Peritoneal Surface Malignancies: Palliative Care Considerations.

.   

Abstract

The Chicago Consensus Working Group provides multidisciplinary recommendations for palliative care specifically related to peritoneal surface malignancies. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, gynecologic oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.

Entities:  

Mesh：

Year:  2020        PMID： 32285272     DOI： 10.1245/s10434-020-08323-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


  47 in total

1.  Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction.

Authors:  F De Conno; A Caraceni; E Zecca; E Spoldi; V Ventafridda
Journal:  J Pain Symptom Manage       Date:  1991-11       Impact factor: 3.612

2.  Practice Patterns of Medications for Patients With Malignant Bowel Obstruction Using a Nationwide Claims Database and the Association Between Treatment Outcomes and Concomitant Use of H2-Blockers/Proton Pump Inhibitors and Corticosteroids With Octreotide.

Authors:  Takaaki Minoura; Masato Takeuchi; Tatsuya Morita; Koji Kawakami
Journal:  J Pain Symptom Manage       Date:  2017-11-06       Impact factor: 3.612

3.  Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.

Authors:  David C Currow; Stephen Quinn; Meera Agar; Belinda Fazekas; Janet Hardy; Nikki McCaffrey; Simon Eckermann; Amy P Abernethy; Katherine Clark
Journal:  J Pain Symptom Manage       Date:  2014-11-14       Impact factor: 3.612

Review 4.  Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer.

Authors:  D J Feuer; K E Broadley; J H Shepherd; D P Barton
Journal:  Cochrane Database Syst Rev       Date:  2000

5.  Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction.

Authors:  Takayuki Hisanaga; Takuya Shinjo; Tatsuya Morita; Nobuhisa Nakajima; Masayuki Ikenaga; Masahito Tanimizu; Yoshiyuki Kizawa; Takami Maeno; Yasuo Shima; Ichinosuke Hyodo
Journal:  Jpn J Clin Oncol       Date:  2010-04-21       Impact factor: 3.019

6.  Reducing gastric secretions--a role for histamine 2 antagonists or proton pump inhibitors in malignant bowel obstruction?

Authors:  K Clark; L Lam; D Currow
Journal:  Support Care Cancer       Date:  2009-03-17       Impact factor: 3.603

7.  Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction.

Authors:  Yasuo Shima; Atshushi Ohtsu; Kuniaki Shirao; Yasutsuna Sasaki
Journal:  Jpn J Clin Oncol       Date:  2008-05       Impact factor: 3.019

8.  Nonopioid pharmacological management of malignant bowel obstruction: a New Zealand-wide survey.

Authors:  Dipti L Mittal; Anubhav Mittal; Eileen A Brosnan; Willem J Landman
Journal:  J Palliat Med       Date:  2014-08-27       Impact factor: 2.947

9.  Palliation of malignant intestinal obstruction using octreotide.

Authors:  D Khoo; E Hall; R Motson; J Riley; K Denman; J Waxman
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

10.  Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.

Authors:  Xingang Peng; Peige Wang; Shikuan Li; Guangyong Zhang; Sanyuan Hu
Journal:  World J Surg Oncol       Date:  2015-02-15       Impact factor: 2.754
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.